Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells

Journal of Immunology

Volumn 167, Issue 3, 2001, Pages 1795-1802

  Motta, I ^a   Andre F ^a   Lim, A ^a   Tartaglia, J ^a   Cox, W I ^a   Zitvogel, L ^a   Angevin, E ^a   Kourilsky, P ^a  

^a Institute National de la Santé   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHORDOPOXVIRINAE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS REACTION; CYTOTOXICITY; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMAGE CYTOMETRY; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0035425003     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.3.1795     Document Type: Article

References (43)

1. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
2. Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability
3. Proliferating dendrific cell progenitors in human blood
4. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
5. Bone marrow-derived dendritic cells pulsed with synthethic tumour peptides elicit protective and therapeutic antitumour immunity
6. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
7. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
8. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
9. Dendritic cell vaccines for cancer immunotherapy
10. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
11. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection
12. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen
13. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
14. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
15. Induction of antitumor immunity with dendritic cells transduced with adenovirus-encoding endogenous tumor-associated antigens
16. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells
17. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
18. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus vaccine
19. Dendritic cells infected with poxviruses encoding Mart-1/Melan A sensitize T lymphocytes in vitro
20. Nonreplicating vital vectors as potential vaccines: Recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins
21. Biological and immunogenic properties of a canarypox-rabies recombinant. ALVAC-RG (vCP65) in non-avian species
22. Applications of pox virus vectors to vaccination: An update
23. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
24. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
25. Diversity of the cytotoxic melanoma-specific immune response
26. Phenotypic analysis of antigen-specific T lymphocytes
27. MN env gene
28. Replication-defective canarypox (Alvac) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy
29. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: Characterization and antigen-specific activation
30. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1
31. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
32. p53 as target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge
33. The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity
34. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guérin organisms, and sensitize mice to mycobacterial antigens in vivo
35. Dendritic cells and the control of immunity
36. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
37. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response
38. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA
39. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function
40. + T cell help
41. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
42. Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen-presenting cells, and cytokines
43. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogeneous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response